These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 10830219)

  • 21. Cholesterol-lowering therapy after heart transplantation: a 12-month randomized trial.
    Pflugfelder PW; Huff M; Oskalns R; Rudas L; Kostuk WJ
    J Heart Lung Transplant; 1995; 14(4):613-22. PubMed ID: 7578166
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia.
    Szczeklik A; Musiał J; Undas A; Gajewski P; Góra P; Swadźba J; Jankowski M
    J Am Coll Cardiol; 1999 Apr; 33(5):1286-93. PubMed ID: 10193729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease.
    Baigent C; Landray M; Leaper C; Altmann P; Armitage J; Baxter A; Cairns HS; Collins R; Foley RN; Frighi V; Kourellias K; Ratcliffe PJ; Rogerson M; Scoble JE; Tomson CR; Warwick G; Wheeler DC
    Am J Kidney Dis; 2005 Mar; 45(3):473-84. PubMed ID: 15754269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early introduction of HMG-CoA reductase inhibitors could prevent the incidence of transplant coronary artery disease.
    Kato T; Tokoro T; Namii Y; Kobayashi T; Hayashi S; Yokoyama I; Morimoto S; Chan M; Giannetti N; Hunt SA
    Transplant Proc; 2000 Mar; 32(2):331-3. PubMed ID: 10715431
    [No Abstract]   [Full Text] [Related]  

  • 25. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment.
    Fiegenbaum M; da Silveira FR; Van der Sand CR; Van der Sand LC; Ferreira ME; Pires RC; Hutz MH
    Clin Pharmacol Ther; 2005 Nov; 78(5):551-8. PubMed ID: 16321621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
    Pappu AS; Bacon SP; Illingworth DR
    J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cholesterol-lowering intervention and coronary artery disease after cardiac transplantation.
    Carrier M; Pelletier GB; Genest J; Cartier R; Leclerc Y; Pelletier LC
    Ann Thorac Surg; 1994 Feb; 57(2):353-6. PubMed ID: 8311595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of interferon-gamma-mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors.
    Sadeghi MM; Tiglio A; Sadigh K; O'Donnell L; Collinge M; Pardi R; Bender JR
    Transplantation; 2001 May; 71(9):1262-8. PubMed ID: 11397960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients.
    Panichi V; Paoletti S; Mantuano E; Manca-Rizza G; Filippi C; Santi S; Taccola D; Donadio C; Tramonti G; Innocenti M; Casto G; Consani C; Sbragia G; Franzoni F; Galetta F; Panicucci E; Barsotti G
    Nephrol Dial Transplant; 2006 Feb; 21(2):337-44. PubMed ID: 16249194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin.
    Arnadottir M; Eriksson LO; Thysell H; Karkas JD
    Nephron; 1993; 65(3):410-3. PubMed ID: 8289991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of low dose simvastatin in cardiac transplant recipients treated with cyclosporine.
    Vanhaecke J; Van Cleemput J; Van Lierde J; Daenen W; De Geest H
    Transplantation; 1994 Jul; 58(1):42-5. PubMed ID: 8036706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fluvastatin as co-medication in heart transplant recipients with elevated creatine-kinase.
    Sadoni S; Kaczmarek I; Delgado O; Schmöckel M; Reichart B; Meiser B
    Transplant Proc; 2007 Mar; 39(2):558-9. PubMed ID: 17362781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA.
    Park HJ; Kong D; Iruela-Arispe L; Begley U; Tang D; Galper JB
    Circ Res; 2002 Jul; 91(2):143-50. PubMed ID: 12142347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Statins and cardiac allograft vasculopathy after heart transplantation.
    Kobashigawa JA
    Semin Vasc Med; 2004 Nov; 4(4):401-6. PubMed ID: 15861321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low-dose simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in ciclosporin-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients.
    Arnadottir M; Eriksson LO; Germershausen JI; Thysell H
    Nephron; 1994; 68(1):57-62. PubMed ID: 7991041
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor therapy in the managed care era.
    Jacobson TA
    Am J Cardiol; 1996 Sep; 78(6A):32-41. PubMed ID: 8875973
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
    Sharma R; Mahajan M; Singh B; Bal BS; Kant R
    J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of simvastatin on tissue factor pathway of blood coagulation in STATCOPE (Simvastatin in the prevention of COPD exacerbations) trial.
    Rao AK; Del Carpio-Cano F; Janapati S; Zhao H; Voelker H; Lu X; Criner G;
    J Thromb Haemost; 2021 Jul; 19(7):1709-1717. PubMed ID: 33638931
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hyperlipidemia, tissue factor, coagulation, and simvastatin.
    Owens AP; Byrnes JR; Mackman N
    Trends Cardiovasc Med; 2014 Apr; 24(3):95-8. PubMed ID: 24016468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment.
    Ansell BJ; Navab M; Hama S; Kamranpour N; Fonarow G; Hough G; Rahmani S; Mottahedeh R; Dave R; Reddy ST; Fogelman AM
    Circulation; 2003 Dec; 108(22):2751-6. PubMed ID: 14638544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.